Virus-fighting startup Singletto closed a $10 million Series A investment round and is now selling its pathogen-killing face masks on Amazon. The Seattle company was also selected by the U.S. Defense ...
The FDA has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis, a rare, progressive lung disease that can cause scarring and breathing difficulties. The approval marks the ...
Share on Pinterest The FDA recently approved a generic abortion pill that’s considered as safe and effective as mifepristone. Shuran Huang for The Washington Post via Getty Images The approval, ...
The updated indications state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy. The Food ...
Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...
Nearly every Republican senator signed a letter Thursday urging the Food and Drug Administration (FDA) to reverse its decision to approve a “generic” version of the abortion pill mifepristone, which ...
The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...
The FDA approved updated labeling for Carvykti (ciltacabtagene autoleucel, Janssen Biotech) to include a new boxed warning for immune effector cell-associated enterocolitis (IEC-EC). Carvykti is a ...
New Mexico’s ‘Free’ Child Care an Attempt to Cover for Past Failures The Virtue of Liberty: A Response to the NatCons Trump Administration Says Drug-Boat Strikes Are Not Really ‘Hostilities,’ as Death ...
In 2022, Regeneron paid Sanofi $900 million to gain full rights to its partnered cancer drug Libtayo. Three years later, the pricey bet on the injected PD-1 inhibitor appears to be paying off.
The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback